VMET
Versamet Royalties Corporation Common StockNASDAQBASIC MATERIALSOTHER PRECIOUS METALS & MINING
Key Statistics
Market Cap
$1.30B
P/E Ratio
38.71
EPS
$0.31
Beta
—
52W High
$15.00
52W Low
$9.10
50-Day MA
$11.90
200-Day MA
$11.40
Dividend Yield
—
Profit Margin
58.40%
Forward P/E
43.67
PEG Ratio
—
About Versamet Royalties Corporation Common Stock
Viamet Pharmaceuticals Corp (VMET) is a biopharmaceutical company dedicated to the development of innovative therapeutics targeting serious and life-threatening diseases, utilizing its proprietary metalloenzyme-based technology platform. Focused on addressing unmet medical needs in the realms of fungal infections and oncology, Viamet is positioned as a key player in therapeutic innovation. With a robust pipeline supported by strategic partnerships and a strong intellectual property portfolio, the company is well-equipped to advance its clinical programs and maximize shareholder value, aiming to transform treatment paradigms in its targeted therapeutic areas.
Fundamentals
| Revenue (TTM) | $55.27M |
| Gross Profit (TTM) | $37.23M |
| EBITDA | $67.34M |
| Operating Margin | 90.60% |
| Return on Equity | 11.20% |
| Return on Assets | 10.90% |
| Revenue/Share (TTM) | $0.58 |
| Book Value | $2.50 |
| Price-to-Book | 3.49 |
| Price-to-Sales (TTM) | 23.57 |
| EV/Revenue | 23.56 |
| EV/EBITDA | 18.56 |
| Quarterly Earnings Growth (YoY) | 573.00% |
| Quarterly Revenue Growth (YoY) | 594.00% |
| Shares Outstanding | $108.59M |
| Float | $25.90M |
| % Insiders | 65.06% |
| % Institutions | 7.58% |
Historical Volatility
HV 10-Day
76.18%
HV 20-Day
76.16%
HV 30-Day
73.55%
HV 60-Day
77.68%
HV Rank
—
Volatility is currently expanding
More BASIC MATERIALS Stocks
Data last updated: 6/13/2026